K
5.00
-1.89 (-27.43%)
| Penutupan Terdahulu | 6.89 |
| Buka | 6.87 |
| Jumlah Dagangan | 350,053 |
| Purata Dagangan (3B) | 722,137 |
| Modal Pasaran | 56,679,956 |
| Harga / Jualan (P/S) | 251.08 |
| Harga / Buku (P/B) | 3.09 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 May 2025 - 29 May 2025 |
| Margin Operasi (TTM) | -42,029.54% |
| EPS Cair (TTM) | -29.16 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 557,150.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.82% |
| Nisbah Semasa (MRQ) | 0.210 |
| Aliran Tunai Operasi (OCF TTM) | -11.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.16 M |
| Pulangan Atas Aset (ROA TTM) | -85.55% |
| Pulangan Atas Ekuiti (ROE TTM) | -3,891.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Kazia Therapeutics Limited | Menaik | Menaik |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.25 |
|
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.09% |
| % Dimiliki oleh Institusi | 8.22% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Arax Advisory Partners | 30 Sep 2025 | 200 |
| Mai Capital Management | 30 Sep 2025 | 52 |
| Julat 52 Minggu | ||
| Median | 18.00 (260.00%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Dec 2025 | 18.00 (260.00%) | Beli | 10.43 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |